Thermo Fisher, Genovis Collaborate to Advance Characterization and Monitoring Methods

Published on: 

The companies will join forces on a research project to develop end-to-end workflows for the preparation, characterization, and monitoring of biotherapeutics using liquid chromatography-mass spectrometry.

Thermo Fisher Scientific and Genovis, a provider of enzyme products for biological drug development, announced on April 8, 2019 that the companies have entered a collaborative research project to develop end-to-end workflows for the preparation, characterization, and monitoring of novel and complex biotherapeutics using liquid chromatography–mass spectrometry (LC–MS).

Bringing together Thermo Fisher's LC–MS technology with Genovis’ enzyme-based sample preparation and analysis techniques, the collaboration will enable the development of robust, automation-ready, magnetic bead and chromatography-based workflows meant to streamline biotherapeutic analysis. The combination of the Thermo Scientific Vanquish Duo UHPLC Systems (with Dual LC workflow) and the Thermo Scientific Chromeleon Chromatography Data System (CDS) Software with the SmartEnzyme technology from Genovis will enable the development of LC–MS-based protocols for O-glycosylation profiling and automated high-throughput workflows for critical quality attribute (CQA) analysis of monoclonal antibodies at the subunit level. Thermo Fisher's global customer solution centers will also offer Genovis its expertise in determining optimal hardware/software configurations and suitable consumables for CQA analysis of biotherapeutics during the research and development phase.

"With the shift toward large biological entities, companies are aiming to bring to market medicines with greater affinity and efficacy, but these medicines also present an additional level of analytical complexity," said John Rontree, senior director, global marketing and strategy, pharmaceuticals and biopharmaceuticals, Thermo Fisher Scientific, in a company press release. "By collaborating with Genovis, we plan to develop comprehensive workflows that provide robust and advanced solutions for preparing and assessing complex biotherapeutics."


"We are excited to work with Thermo Fisher Scientific to continue our goal toward more automated analytical workflows," said Fredrick Olsson, CEO at Genovis, in the release. "Through this collaboration, we will be able to develop new products and workflows on world-class instrumentation together with experts from Thermo Fisher's European [b]iopharma [c]ustomer [s]olution [c]enter and serve the growing analytical needs of biopharma customers of both companies with meaningful innovations."

Source: Thermo Fisher Scientific